CN102459227B - Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 - Google Patents
Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 Download PDFInfo
- Publication number
- CN102459227B CN102459227B CN201080027641.6A CN201080027641A CN102459227B CN 102459227 B CN102459227 B CN 102459227B CN 201080027641 A CN201080027641 A CN 201080027641A CN 102459227 B CN102459227 B CN 102459227B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- phenyl
- methyl
- prepared
- azetidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*CC(C)NC(CNC(c1cc(C(F)(F)F)ccc1)=O)=O Chemical compound C*CC(C)NC(CNC(c1cc(C(F)(F)F)ccc1)=O)=O 0.000 description 1
- FYTMPPOAWMMTGA-UHFFFAOYSA-N CC(C)(C)OC(Nc(cc1)ccc1C(CC1)=CCC1=O)=O Chemical compound CC(C)(C)OC(Nc(cc1)ccc1C(CC1)=CCC1=O)=O FYTMPPOAWMMTGA-UHFFFAOYSA-N 0.000 description 1
- DUPKTFVNPHZWNC-UHFFFAOYSA-N CC(C)(C)OC(Nc1cccc(C(CC2)(CCC22OCCO2)O)c1)=O Chemical compound CC(C)(C)OC(Nc1cccc(C(CC2)(CCC22OCCO2)O)c1)=O DUPKTFVNPHZWNC-UHFFFAOYSA-N 0.000 description 1
- RVGRTRHVBFCARF-UHFFFAOYSA-N CC(C)(C)OC(Nc1cccc(C(CC2)(CCC2N(C2)CC2NC(CNC(c2cc(C(F)(F)F)ccc2)=O)=O)O)c1)=O Chemical compound CC(C)(C)OC(Nc1cccc(C(CC2)(CCC2N(C2)CC2NC(CNC(c2cc(C(F)(F)F)ccc2)=O)=O)O)c1)=O RVGRTRHVBFCARF-UHFFFAOYSA-N 0.000 description 1
- FHENRZKRAUSKEY-ARLHGKGLSA-N CC(CC[C@@H](C)N(C1)CC1NC(CN)=O)C1=CC=CCC1 Chemical compound CC(CC[C@@H](C)N(C1)CC1NC(CN)=O)C1=CC=CCC1 FHENRZKRAUSKEY-ARLHGKGLSA-N 0.000 description 1
- TWTISSNNQCPARJ-UHFFFAOYSA-N CCOC(c1cccc(C(CC2)CCC2=O)c1)=O Chemical compound CCOC(c1cccc(C(CC2)CCC2=O)c1)=O TWTISSNNQCPARJ-UHFFFAOYSA-N 0.000 description 1
- OUWPXYDIJLVUSG-UHFFFAOYSA-N COc1cc(C(CC2)(CCC2=O)O)ccc1 Chemical compound COc1cc(C(CC2)(CCC2=O)O)ccc1 OUWPXYDIJLVUSG-UHFFFAOYSA-N 0.000 description 1
- XUXGRGHZAIOCSD-UHFFFAOYSA-N COc1cccc(C(CC2)(CCC2N(C2)CC2NC(CNC(c2cc(C(F)(F)F)ccc2)=O)=O)N)c1 Chemical compound COc1cccc(C(CC2)(CCC2N(C2)CC2NC(CNC(c2cc(C(F)(F)F)ccc2)=O)=O)N)c1 XUXGRGHZAIOCSD-UHFFFAOYSA-N 0.000 description 1
- YODHYTBRRINSKP-UHFFFAOYSA-N COc1ccccc1C(CC1)(CCC1N(C1)CC1NC(CNC(c1cc(C(F)(F)F)ccc1)=C)=O)O Chemical compound COc1ccccc1C(CC1)(CCC1N(C1)CC1NC(CNC(c1cc(C(F)(F)F)ccc1)=C)=O)O YODHYTBRRINSKP-UHFFFAOYSA-N 0.000 description 1
- ZRUKZXVNNVHEBW-UHFFFAOYSA-N C[n]1c(cc(C(CC2)(CCC2=O)O)cc2)c2nc1 Chemical compound C[n]1c(cc(C(CC2)(CCC2=O)O)cc2)c2nc1 ZRUKZXVNNVHEBW-UHFFFAOYSA-N 0.000 description 1
- COHHDKBOPDVULP-UHFFFAOYSA-N Cc1ccc(C(CC2)(CCC2=O)O)cc1 Chemical compound Cc1ccc(C(CC2)(CCC2=O)O)cc1 COHHDKBOPDVULP-UHFFFAOYSA-N 0.000 description 1
- FREHTPKNPMUSMK-UHFFFAOYSA-N N#Cc1cc(C(CC2)=CCC2=O)ccc1 Chemical compound N#Cc1cc(C(CC2)=CCC2=O)ccc1 FREHTPKNPMUSMK-UHFFFAOYSA-N 0.000 description 1
- JXNHEUAANNGFFV-UHFFFAOYSA-N NC(CC1)(CCC1=O)c1ccccc1 Chemical compound NC(CC1)(CCC1=O)c1ccccc1 JXNHEUAANNGFFV-UHFFFAOYSA-N 0.000 description 1
- VZQQLYFMKYCMQZ-UHFFFAOYSA-N O=C(CC1)CC=C1c(cc1)ccc1N=O Chemical compound O=C(CC1)CC=C1c(cc1)ccc1N=O VZQQLYFMKYCMQZ-UHFFFAOYSA-N 0.000 description 1
- LIDGWINURFOALA-UHFFFAOYSA-N O=C(CNC(c(cc1)cc(C(F)(F)F)c1F)=O)NC1CNC1 Chemical compound O=C(CNC(c(cc1)cc(C(F)(F)F)c1F)=O)NC1CNC1 LIDGWINURFOALA-UHFFFAOYSA-N 0.000 description 1
- GRIUVLWWKAQKDF-UHFFFAOYSA-N O=C(CNC(c1cc(C(F)(F)F)ccc1)=O)NC(C1)CN1C(CC1)CCC1c1ccc(CCN2)c2c1 Chemical compound O=C(CNC(c1cc(C(F)(F)F)ccc1)=O)NC(C1)CN1C(CC1)CCC1c1ccc(CCN2)c2c1 GRIUVLWWKAQKDF-UHFFFAOYSA-N 0.000 description 1
- WEMZPTVFMJNMRK-UHFFFAOYSA-N OC(CC1)(CCC1=O)c(cc1)ccc1Cl Chemical compound OC(CC1)(CCC1=O)c(cc1)ccc1Cl WEMZPTVFMJNMRK-UHFFFAOYSA-N 0.000 description 1
- JAVULHNIYKQECV-UHFFFAOYSA-N OC(CC1)(CCC1=O)c1cccc(O)c1 Chemical compound OC(CC1)(CCC1=O)c1cccc(O)c1 JAVULHNIYKQECV-UHFFFAOYSA-N 0.000 description 1
- CJRVNLPYFHEJPE-UHFFFAOYSA-N OC(CC1)(CCC1N(C1)CC1NC(CNC(c1cc(C(F)(F)F)ccc1)=O)=O)c(cc1)ccc1O Chemical compound OC(CC1)(CCC1N(C1)CC1NC(CNC(c1cc(C(F)(F)F)ccc1)=O)=O)c(cc1)ccc1O CJRVNLPYFHEJPE-UHFFFAOYSA-N 0.000 description 1
- PRNCENABYSAGEY-UHFFFAOYSA-N Oc(cc1)ccc1C(CC1)=CCC1=O Chemical compound Oc(cc1)ccc1C(CC1)=CCC1=O PRNCENABYSAGEY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17030709P | 2009-04-17 | 2009-04-17 | |
| US61/170,307 | 2009-04-17 | ||
| US61/170307 | 2009-04-17 | ||
| PCT/US2010/031265 WO2010121046A1 (en) | 2009-04-17 | 2010-04-15 | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102459227A CN102459227A (zh) | 2012-05-16 |
| CN102459227B true CN102459227B (zh) | 2014-08-20 |
Family
ID=42167720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080027641.6A Expired - Fee Related CN102459227B (zh) | 2009-04-17 | 2010-04-15 | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100267689A1 (enExample) |
| EP (1) | EP2419419B1 (enExample) |
| JP (1) | JP5675773B2 (enExample) |
| KR (1) | KR20120006544A (enExample) |
| CN (1) | CN102459227B (enExample) |
| AR (1) | AR076328A1 (enExample) |
| AU (1) | AU2010236346B2 (enExample) |
| BR (1) | BRPI1016189A2 (enExample) |
| CA (1) | CA2758934A1 (enExample) |
| ES (1) | ES2528625T3 (enExample) |
| MX (1) | MX2011010964A (enExample) |
| NZ (1) | NZ595432A (enExample) |
| TW (1) | TW201102377A (enExample) |
| WO (1) | WO2010121046A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2745969C (en) | 2008-12-10 | 2017-04-25 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 |
| CN102459225B (zh) * | 2009-04-16 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-杂芳基-环己烷拮抗剂 |
| NZ595432A (en) | 2009-04-17 | 2013-12-20 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| BRPI1016205A2 (pt) | 2009-04-17 | 2016-04-19 | Janssen Pharmaceutica Nv | compostos de cicloexano ligado a 4-azetidinil-1-heteroátomo antagonistas de ccr2 |
| TW201211027A (en) * | 2010-06-09 | 2012-03-16 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
| ES2550312T3 (es) | 2010-06-17 | 2015-11-06 | Janssen Pharmaceutica Nv | Antagonistas ciclohexil-azetidinilo de CCR2 |
| WO2013060865A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| IN2014KN01075A (enExample) | 2011-11-18 | 2015-10-09 | Heptares Therapeutics Ltd | |
| AU2012345779B2 (en) * | 2011-12-01 | 2017-04-06 | Chemocentryx, Inc. | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists |
| JP5977349B2 (ja) | 2012-06-15 | 2016-08-24 | 田辺三菱製薬株式会社 | 芳香族複素環化合物 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| HRP20201416T1 (hr) | 2014-10-24 | 2020-12-11 | Landos Biopharma, Inc. | Terapeutska sredstva na bazi sintetaze lantionin c-sličan 2 |
| EP3050574B1 (en) | 2015-01-28 | 2019-10-09 | Universite De Bordeaux | Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease |
| RS62809B1 (sr) | 2015-05-21 | 2022-02-28 | Chemocentryx Inc | Modulatori ccr2 |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| BR112020005284A2 (pt) | 2017-09-25 | 2020-09-24 | Chemocentryx, Inc. | terapia de combinação usando um antagonista do receptor de quimiocina 2 (ccr2) e um inibidor de pd-1/pd-l1 |
| MX2020005525A (es) | 2017-11-30 | 2020-10-28 | Landos Biopharma Inc | Tratamientos con ligandos de proteína 2 similar a lantionina c y células preparadas con estos. |
| CA3087765A1 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN110028395A (zh) * | 2019-05-29 | 2019-07-19 | 宁夏中星显示材料有限公司 | 一种4-(4-羟基苯基)环己酮的制备方法 |
| WO2021127472A1 (en) | 2019-12-20 | 2021-06-24 | Landos Biopharma, Inc. | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030004151A1 (en) * | 2000-12-20 | 2003-01-02 | Robert Cherney | Cyclic derivatives as modulators of chemokine receptor activity |
| CN1741994A (zh) * | 2002-11-27 | 2006-03-01 | 因塞特公司 | 作为趋化因子受体调节剂的3－氨基吡咯烷衍生物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037354A (en) * | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| JP2002505684A (ja) | 1997-06-18 | 2002-02-19 | メルク エンド カンパニー インコーポレーテッド | α１ａアドレナリン受容体拮抗薬 |
| WO2000069815A1 (en) * | 1999-05-13 | 2000-11-23 | Teijin Limited | Ureido-substituted cyclic amine derivatives and their use as drug |
| AU779610B2 (en) | 1999-08-04 | 2005-02-03 | Teijin Limited | Cyclic amine CCR3 antagonists |
| CA2390531A1 (en) | 1999-11-08 | 2001-05-17 | Wyeth | ¬(indol-3-yl)-cycloalkyl|-3-substituted azetidines for the treatment of central nervous system disorders |
| US6245799B1 (en) * | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| CN1250605C (zh) * | 2001-03-26 | 2006-04-12 | 拜尔公司 | 具有显著剪切变稀行为的聚碳酸酯 |
| WO2004050024A2 (en) * | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| KR20080052683A (ko) | 2003-12-18 | 2008-06-11 | 인사이트 코포레이션 | 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체 |
| AU2005290028A1 (en) * | 2004-09-28 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Substituted dipiperdine CCR2 antagonists |
| UY29219A1 (es) * | 2004-11-22 | 2006-04-28 | Incyte Corp | Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida |
| GB0513747D0 (en) | 2005-07-06 | 2005-08-10 | Merck Sharp & Dohme | Therapeutic compounds |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| US20070197590A1 (en) | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
| CL2007002958A1 (es) * | 2006-10-12 | 2008-05-09 | Epix Delaware Inc | Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr |
| AU2008335135A1 (en) * | 2007-12-11 | 2009-06-18 | Cytopathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
| CA2745969C (en) * | 2008-12-10 | 2017-04-25 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 |
| CN102459225B (zh) * | 2009-04-16 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-杂芳基-环己烷拮抗剂 |
| NZ595432A (en) | 2009-04-17 | 2013-12-20 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| BRPI1016205A2 (pt) * | 2009-04-17 | 2016-04-19 | Janssen Pharmaceutica Nv | compostos de cicloexano ligado a 4-azetidinil-1-heteroátomo antagonistas de ccr2 |
-
2010
- 2010-04-15 NZ NZ595432A patent/NZ595432A/en not_active IP Right Cessation
- 2010-04-15 EP EP10714804.1A patent/EP2419419B1/en active Active
- 2010-04-15 MX MX2011010964A patent/MX2011010964A/es active IP Right Grant
- 2010-04-15 KR KR1020117026846A patent/KR20120006544A/ko not_active Withdrawn
- 2010-04-15 AU AU2010236346A patent/AU2010236346B2/en not_active Ceased
- 2010-04-15 WO PCT/US2010/031265 patent/WO2010121046A1/en not_active Ceased
- 2010-04-15 BR BRPI1016189A patent/BRPI1016189A2/pt not_active Application Discontinuation
- 2010-04-15 ES ES10714804.1T patent/ES2528625T3/es active Active
- 2010-04-15 CA CA2758934A patent/CA2758934A1/en not_active Abandoned
- 2010-04-15 JP JP2012506232A patent/JP5675773B2/ja not_active Expired - Fee Related
- 2010-04-15 US US12/761,080 patent/US20100267689A1/en not_active Abandoned
- 2010-04-15 CN CN201080027641.6A patent/CN102459227B/zh not_active Expired - Fee Related
- 2010-04-16 TW TW099111898A patent/TW201102377A/zh unknown
- 2010-04-19 AR ARP100101287A patent/AR076328A1/es unknown
-
2011
- 2011-10-25 US US13/280,690 patent/US8513229B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030004151A1 (en) * | 2000-12-20 | 2003-01-02 | Robert Cherney | Cyclic derivatives as modulators of chemokine receptor activity |
| CN1741994A (zh) * | 2002-11-27 | 2006-03-01 | 因塞特公司 | 作为趋化因子受体调节剂的3－氨基吡咯烷衍生物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8513229B2 (en) | 2013-08-20 |
| US20100267689A1 (en) | 2010-10-21 |
| CA2758934A1 (en) | 2010-10-21 |
| EP2419419A1 (en) | 2012-02-22 |
| JP2012524111A (ja) | 2012-10-11 |
| CN102459227A (zh) | 2012-05-16 |
| MX2011010964A (es) | 2011-11-02 |
| BRPI1016189A2 (pt) | 2016-04-19 |
| WO2010121046A1 (en) | 2010-10-21 |
| KR20120006544A (ko) | 2012-01-18 |
| JP5675773B2 (ja) | 2015-02-25 |
| EP2419419B1 (en) | 2014-12-03 |
| AU2010236346B2 (en) | 2015-01-22 |
| AR076328A1 (es) | 2011-06-01 |
| AU2010236346A1 (en) | 2011-11-03 |
| NZ595432A (en) | 2013-12-20 |
| US20120040960A1 (en) | 2012-02-16 |
| TW201102377A (en) | 2011-01-16 |
| ES2528625T3 (es) | 2015-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102459227B (zh) | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 | |
| CN102459226B (zh) | Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂 | |
| CN102459225B (zh) | Ccr2的4-氮杂环丁烷基-1-杂芳基-环己烷拮抗剂 | |
| ES2550312T3 (es) | Antagonistas ciclohexil-azetidinilo de CCR2 | |
| JP6110474B2 (ja) | Ｃｃｒ２の縮合シクロペンチル拮抗薬 | |
| MX2011006904A (es) | Compuesto heterociclico biciclico novedoso. | |
| SG171998A1 (en) | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 | |
| JP5530430B2 (ja) | Ｃｃｒ２のピペリジルアクリルアミドアンタゴニスト | |
| JP6204983B2 (ja) | Ｃｃｒ２のオクタヒドロ−シクロペンタピロリル拮抗薬 | |
| EP2580208B1 (en) | Cyclohexyl-azetidinyl antagonists of ccr2 | |
| CN103228644B (zh) | Ccr2的4-取代-环己基氨基-4-哌啶基-乙酰胺拮抗剂 | |
| JPWO2003072545A1 (ja) | 環状アミン化合物及びそれを有効成分とするｃｃｒ３阻害薬 | |
| HK1162504B (en) | Novel bicyclic heterocyclic compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Xuqing Inventor after: Hufnagel Heather Inventor after: Hou Cuibin Inventor after: Johnson Dana L. Inventor after: Sui Zhihua Inventor before: Zhang Xuqing Inventor before: Hufnagel Heather Inventor before: C *hou Inventor before: Johnson Dana L. Inventor before: Sui Zhihua |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG XUQING HUFNAGEL HEATHER HOU CULFEN JOHNSON DANA L. SUI ZHIHUA TO: ZHANG XUQING HUFNAGEL HEATHER HOU CUIBIN JOHNSON DANA L. SUI ZHIHUA |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140820 Termination date: 20180415 |